Frequencies of polymorphisms in genes affecting the pharmacokinetics of warfarin in the Zaporizhzhia region
Open Access
- 1 July 2021
- journal article
- research article
- Published by Zaporizhzhia State Medical and Pharmaceutical University in Zaporozhye Medical Journal
- Vol. 23 (4), 476-479
- https://doi.org/10.14739/2310-1210.2021.4.227002
Abstract
The aim of the study: to establish the frequencies of polymorphisms in VKORC1, CYP2C9 and CYP4F2 genes among residents of the Zaporizhzhia region. Materials and methods. A total of 150 persons (62 male, 88 female) with a median age of 46 years (26; 58) undergoing preventive examination at the Medical Educational and Scientific Center "University Clinic" of Zaporizhzhia State Medical University (ZSMU). The CYP2C9, CYP4F2, VKORC1 genes polymorphisms in atrial fibrillation patients were determined in the Department of Molecular Genetic Studies of the ZSMU Medical Laboratory Center. Amplification of DNA fragments containing polymorphic regions was performed using multiplex real time polymerase chain reaction with Warfarin Pharmacogenetics kits (LLC NPO DNA Technology) in a CFX-96 thermocycler (BioRad) with a fluorescence detection scheme. Results. It was determined that among Zaporizhzhia region residents, the frequencies of CYP2C9*2 genotypes were: C/C 77.3 %, C/T - 22.7 %, T/T - 0; CYP2C9*3 genotypes: A/A - 88.7 %, A/C - 10.7 %, C/C - 0.6 %; CYP4F2 genotypes: C/C - 56.0 %, C/T - 35.3 %, T/T - 8.7 %; VKORC1 genotypes: G/G - 38.0 %, G/A - 50.0 %, A/A - 12.0 %. There were no statistically significant differences in the distribution of genotype frequencies between males and females and between different age groups. The frequencies of CYP2C9, CYP4F2, VKORC1 genotypes in different populations were compared. Their variability in different geographic regions was established. Conclusions. CYP4F2 and VKORC1 genes polymorphisms are more common in the Zaporizhzhia region, while the prevalence of CYP2C9*2 and CYP2C9*3 genes polymorphisms is much lower. It is necessary to take into account the prevalence of genes polymorphisms that affect warfarin metabolism for each individual population to select its dose by pharmacogenetic testing.This publication has 14 references indexed in Scilit:
- Comparative Stroke, Bleeding, and Mortality Risks in Older Medicare Patients Treated with Oral Anticoagulants for Nonvalvular Atrial FibrillationThe American Journal of Medicine, 2019
- Value of VKORC1 (−1639G>A) rs9923231 genotyping in predicting warfarin dose: A replication study in South Indian populationIndian Heart Journal, 2018
- Pharmacogenetics-based personalized therapy: Levels of evidence and recommendations from the French Network of Pharmacogenetics (RNPGx)Therapies, 2017
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics‐Guided Warfarin Dosing: 2017 UpdateClinical Pharmacology & Therapeutics, 2017
- The Influence of CYP2C9 and VKORC1 Gene Polymorphisms on the Response to Warfarin in EgyptiansIndian Journal of Hematology and Blood Transfusion, 2016
- Impact of the CYP4F2 gene polymorphisms on the warfarin maintenance dose: A systematic review and meta-analysisBiomedical Reports, 2016
- Analysis of CYP2C9*2,CYP2C9*3 and VKORC1 ‐1639 G>A polymorphisms in a population from South‐Eastern EuropeJournal of Cellular and Molecular Medicine, 2012
- Pharmacogenomics of Warfarin dose requirements in HispanicsBlood Cells, Molecules, and Diseases, 2011
- Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirementsJournal of Human Genetics, 2010
- Genotypes of vitamin K epoxide reductase, γ-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patientsThrombosis Research, 2007